Evidence map›Paper›PMID 35074661›Full record

ReviewCurrent opinion in pharmacology2022

Neuroinflammation in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection: Pathogenesis and clinical manifestations.

Graciela Cárdenas, Gladis Fragoso, Edda Sciutto

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Graciela CárdenasDepartment of Neurology. Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
Gladis FragosoDepartment of Immunology. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Edda SciuttoDepartment of Immunology. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Universidad Nacional Autónoma de México · MXInstituto Nacional de Neurología y Neurocirugía · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral inflammation and neuroinflammation are host-mounted to eliminate injury, infection, or toxin to restore homeostasis. However, when inflammation persists, it may promote collateral tissue damage that ultimately culminates in pathological peripheral damage or neurodegeneration. Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) pandemic, responsible of Coronavirus disease 2019 (COVID-19), accumulating evidence describes neurological manifestations and complications worldwide particularly in approximately one-third of patients with COVID-19 particularly in those affected with the severe forms of the disease. Different access routes to the central nervous system have been identified. One immediately used is the entrance by the olfactory and trigeminus nervous affecting olfactory and sensory nerve endings when individuals get the infection by the intranasal route. It can also reach the central nervous system through the choroid plexuses and periventricular areas that lack blood-brain barrier or by its disruption by the exacerbated peripheral inflammation. Until now, the long-term sequelae of SARS-CoV-2 infection is still under research and the post-COVID syndrome. This review focuses on the consequences of the neuroinflammatory response in patients with COVID-19 considering its potential relevance in the appearance of neurological sequelae including neurodegenerative disorders.

Indexed as

COVID-19Nervous System DiseasesHumansInflammationNeuroinflammatory DiseasesPandemicsSARS-CoV-2

Identifiers

PMID35074661
PMCPMC8782621
OpenAlexW4205973989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.